Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CERo Therapeutics HoldingsCERO -4.23% EV-to-OCF is -0.52 as of Aug. 12, 2026. The stock has 2 warning signs investors should review. Among 1,407 Biotechnology companies, CERo Therapeutics Holdings ranks worse than 67.8% on this metric.
The historical rank and industry rank for CERo Therapeutics Holdings's EV-to-OCF or its related term are showing as below:
CERO'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.52 Med: 0 Max: -0.51
Current: -0.52
During the past 5 years, the highest EV-to-OCF of CERo Therapeutics Holdings was -0.51. The lowest was -0.52. And the median was .
CERO's EV-to-OCF is ranked worse than 67.8% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs CERO: -0.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CERo Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:
CERo Therapeutics Holdings's share price for today is $0.0102.
CERo Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.306.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CERo Therapeutics Holdings EV-to-OCF Related Terms
CERo Therapeutics Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CERo Therapeutics Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CERo Therapeutics Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where CERo Therapeutics Holdings's EV-to-OCF falls into.
CERo Therapeutics Holdings's current Enterprise Value is $7.42 Mil.
CERo Therapeutics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERo Therapeutics Holdings (CERO) has a EV-to-OCF of -0.52 as of Aug. 12, 2026. According to the industry distribution chart, CERo Therapeutics Holdings ranks #954 out of 1407 companies in the Biotechnology industry, placing it in the top 67.8%.
Is CERo Therapeutics Holdings' EV-to-OCF too high?
CERo Therapeutics Holdings' current EV-to-OCF is -0.52. Based on the distribution chart, CERo Therapeutics Holdings ranks #954 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint.
How does CERo Therapeutics Holdings' EV-to-OCF compare to PTIX and CYTOF?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #954 out of 1407 companies for EV-to-OCF. This places CERo Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. CERo Therapeutics Holdings's current EV-to-OCF is -0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current EV-to-OCF of -0.52. The current EV-to-OCF is -0.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current EV-to-OCF is -0.52 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERO has been successfully added to your 
